Co-Authors
This is a "connection" page, showing publications co-authored by Gionata Fiorino and Silvio Danese.
Connection Strength
13.312
-
Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. Am J Gastroenterol. 2020 10; 115(10):1719-1721.
Score: 0.906
-
Inflammatory Bowel Disease Care in the COVID-19 Pandemic Era: The Humanitas, Milan, Experience. J Crohns Colitis. 2020 Sep 16; 14(9):1330-1333.
Score: 0.903
-
Protecting patients with IBD during the COVID-19 pandemic. Lancet Gastroenterol Hepatol. 2020 07; 5(7):639.
Score: 0.883
-
Clinician Education and Adoption of Preventive Measures for COVID-19: A Survey of a Convenience Sample of General Practitioners in Lombardy, Italy. Ann Intern Med. 2020 09 01; 173(5):405-407.
Score: 0.877
-
Effectiveness of Infliximab Biosimilar in Crohn's Disease: A Dime, A Dozen. Gastroenterology. 2019 06; 156(8):2349-2351.
Score: 0.820
-
Anti-TNF Biosimilars in Inflammatory Bowel Disease: Searching the Proper Patient's Profile. Curr Med Chem. 2019; 26(2):280-287.
Score: 0.802
-
JAK inhibitors: Novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:89-93.
Score: 0.769
-
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):601-606.
Score: 0.755
-
The safety of biological pharmacotherapy for the treatment of ulcerative colitis. Expert Opin Drug Saf. 2017 Apr; 16(4):437-443.
Score: 0.708
-
Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. J Clin Med. 2020 Oct 31; 9(11).
Score: 0.228
-
Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: Experience from humanitas center, Milan. Pharmacol Res. 2020 10; 160:105061.
Score: 0.223
-
Maintaining the Quality Standards of Care for Inflammatory Bowel Disease Patients During the COVID-19 Pandemic. Clin Gastroenterol Hepatol. 2020 07; 18(8):1882-1883.
Score: 0.219
-
Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019 07 17; 25(8):1399-1407.
Score: 0.208
-
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. 2019; 12:1756284819848631.
Score: 0.206
-
Noninvasive Multimodal Methods to Differentiate Inflamed vs Fibrotic Strictures in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2019 11; 17(12):2397-2415.
Score: 0.205
-
Illness Perception in Inflammatory Bowel Disease Patients is Different Between Patients With Active Disease or in Remission: A Prospective Cohort Study. J Crohns Colitis. 2019 Mar 30; 13(4):417-423.
Score: 0.204
-
Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy. 2019 05; 11(7):565-575.
Score: 0.203
-
Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study. J Crohns Colitis. 2018 Nov 28; 12(12):1385-1391.
Score: 0.199
-
Comparative Accuracy of Bowel Ultrasound Versus Magnetic Resonance Enterography in Combination With Colonoscopy in Assessing Crohn's Disease and Guiding Clinical Decision-making. J Crohns Colitis. 2018 Nov 15; 12(11):1280-1287.
Score: 0.199
-
The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. Aliment Pharmacol Ther. 2018 11; 48(9):941-950.
Score: 0.197
-
PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs. 2018 Jul; 27(7):623-629.
Score: 0.194
-
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018 07; 27(7):595-599.
Score: 0.194
-
Can IL-23 be a good target for ulcerative colitis? Best Pract Res Clin Gastroenterol. 2018 Feb - Apr; 32-33:95-102.
Score: 0.192
-
Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
Score: 0.190
-
Sexual and reproductive issues and inflammatory bowel disease: a neglected topic in men. Eur J Gastroenterol Hepatol. 2018 Mar; 30(3):316-322.
Score: 0.189
-
Vedolizumab for the treatment of Crohn's disease. Expert Rev Clin Immunol. 2018 03; 14(3):179-189.
Score: 0.189
-
Comparison of two methods for the in-vivo diagnosis of Helicobacter pylori infection using a tablet of 13C-urea. Minerva Gastroenterol Dietol. 2017 Dec; 63(4):319-326.
Score: 0.186
-
Biosimilar Drugs for Inflammatory Bowel Disease: Is Similar Good Enough? Dig Dis Sci. 2017 11; 62(11):2964-2965.
Score: 0.185
-
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion. 2017; 96(3):166-172.
Score: 0.183
-
Early intervention in Crohn's disease: towards disease modification trials. Gut. 2017 12; 66(12):2179-2187.
Score: 0.183
-
MFSD2A Promotes Endothelial Generation of Inflammation-Resolving Lipid Mediators and Reduces ColitisĀ inĀ Mice. Gastroenterology. 2017 11; 153(5):1363-1377.e6.
Score: 0.182
-
Novel therapeutic targets for inflammatory bowel disease. J Autoimmun. 2017 Dec; 85:103-116.
Score: 0.181
-
Filgotinib in Crohn's Disease: JAK Is Back. Gastroenterology. 2017 Aug; 153(2):603-605.
Score: 0.180
-
Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience. Dig Liver Dis. 2017 Aug; 49(8):872-877.
Score: 0.178
-
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. Inflamm Bowel Dis. 2017 02; 23(2):233-243.
Score: 0.176
-
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy. Expert Rev Clin Immunol. 2017 05; 13(5):457-467.
Score: 0.175
-
The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease. Curr Pharm Des. 2017; 23(44):6759-6769.
Score: 0.175
-
Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014 Nov; 8(11):1548-50.
Score: 0.147
-
SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience. Nat Rev Gastroenterol Hepatol. 2020 08; 17(8):507-516.
Score: 0.055
-
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020 07; 69(7):1213-1217.
Score: 0.055
-
Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts. Clin Gastroenterol Hepatol. 2020 08; 18(9):2134-2135.
Score: 0.055
-
Late-onset Crohn's disease: a comparison of disease behaviour and therapy with younger adult patients: the Italian Group for the Study of Inflammatory Bowel Disease 'AGED' study. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1361-1369.
Score: 0.053
-
Corrigendum: Perception of Reproductive Health in Women with Inflammatory Bowel Disease. J Crohns Colitis. 2019 05 27; 13(6):815.
Score: 0.052
-
Are Surgical Rates Decreasing in the Biological Era In IBD? Curr Drug Targets. 2019; 20(13):1356-1362.
Score: 0.050